Efficacy and safety outcomes of dulaglutide by baseline HbA1
Of the 9876 eligible participants, 3921 and 5955 had a baseline HbA1c <7% and 7%, respectively. Mean baseline HbA1c were 6.3% and 8.0% and mean duration of diabetes were 9.0 and 11.6years in the respective subgroups. The <7% subgroup was slightly older and less frequently insulin-treated. There was no evidence of a differential dulaglutide treatment effect on BMI reduction, cardiovascular or safety outcomes of interest between the baseline HbA1c subgroups. Treatment-by-baseline HbA1c group interaction was significant for HbA1c change from baseline (p<0.001), with a greater reduction in the subgroup with higher baseline HbA1c values. Sensitivity analyses by baseline HbA1c subgroups 6.5% and >6.5% showed similar results.

The reduced incidence of cardiovascular events, and the reduction in BMI in participants treated with once-weekly dulaglutide was independent of the baseline HbA1c level. Conversely, participants with a higher baseline HbA1c level had greater reductions in HbA1c. Dulaglutide has a positive benefit-risk profile and can be considered in patients with relatively well-controlled HbA1c levels seeking optimal metabolic control and cardiovascular benefits.

Source: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14760?af=R